Bispecific antibody conjugates in therapeutics.
Bispecific monoclonal antibodies have drawn considerable attention from the research community due to their unique structure against two different antigens. The two-arm structure of bsMAb allows researchers to place a therapeutic agent on one arm while allowing the other to specifically target the disease site. The therapeutic agent can be a drug, toxin, enzyme, DNA, radionuclide, etc. Furthermore, bsMAb may redirect the cytotoxicity of immune effector cells towards the diseased cells or induce a systemic immune response against the target. BsMAb holds great promise for numerous therapeutic needs in the light of: (1) recent breakthroughs in recombinant DNA technology, (2) the increased number of identified disease targets as the result of the completion of human genomic map project, and (3) a better understanding of the mechanism of human immune system. This review focuses on therapeutic applications and production of bsMAb while providing the up-to-date clinical trial information.
Cao
Ying
Y
Abbott Laboratories, Dept. 04A6, Bldg. AP8B, 100 Abbott Park Road, Abbott Park, IL 60064, USA. ying.cao@add.ssw.abbott.com
Lam
Laura
L
D018033:Antibodies, Bispecific / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use; D005818:Genetic Engineering / Q000379:methods; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000922:Immunotoxins / Q000008:administration & dosage / Q000627:therapeutic use; D011355:Prodrugs / Q000008:administration & dosage / Q000627:therapeutic use; D014612:Vaccines / Q000008:administration & dosage / Q000627:therapeutic use
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D016207:Cytokines; D000922:Immunotoxins; D011355:Prodrugs; D014612:Vaccines